CareDx unveils IPO plans; U.S. remote radiology imaging initiative hits Russia;

> Molecular diagnostics company CareDx will pursue an IPO for up to $50 million to fuel the use of next-generation sequencing in new blood tests that monitor heart transplant biomarkers. Story

> Quest Diagnostics ($DGX) said it will offer two of BioMérieux's BRAF mutation companion diagnostics for two of GlaxoSmithKline's ($GSK) melanoma drugs. Story (reg. req.)

> A year after the U.S. Supreme Court ended Myriad Genetics' ($MYGN) legal monopoly on breast-cancer gene testing, efforts to advance more breast cancer gene variants into public databases are accelerating. Story

> A new MRI technique could quicken the diagnosis of traumatic brain injury. Story

> Virtual Radiologic (vRad), a U.S.-based telemedicine and radiology practice, and Ramsay Diagnostics, a network of imaging centers in St. Petersburg and Moscow, will partner to bring U.S. remote radiology imaging services to the Russian market. Release

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.